薬理と治療

Abstract

Objective　To examine the effects of the Aurantiochytrium sp. strain SPA214 on blood pressure in healthy Japanese with systolic blood pressure(SBP)of 130–139 mmHg. Methods　This randomized, double–blind, placebo–controlled, parallel–group comparative study included 137 individuals. Using a computer, 32 participants who met the eligibility criteria were randomly assigned to an Aurantiochytrium algae powder–containing food group (Aurantiochytrium group)or a placebo group(n=16 per group). The participants were instructed to consume one Aurantiochytrium algae powder–containing capsule or placebo daily for 12 weeks. The SBP and diastolic blood pressure(DBP) in the sitting position as well as the flow–mediated dilatation, maximum expansion, and resting diameter of the blood vessel were assessed. The outcomes were the values of these parameters after the 12–week intervention(12 weeks), and the difference in these parameters from the baseline(pre–intervention). The primary outcome was the SBP at 12 weeks. Results　Two participants were excluded from the study for noncompliance. Thus, each group comprised 15 participants. Compared to the placebo group, the measured and change in SBP at 12 weeks were significantly lower in the Aurantiochytrium group. The mean of measured SBP at 12 weeks in the Aurantiochytrium group was <130 mmHg. Moreover, the mean of measured DBP at 12 weeks marginally decreased. No adverse events attributable to the ingested test foods were observed. Conclusion　Consuming food containing Aurantiochytrium algae powder for 12 weeks may significantly lower SBP and DBP in healthy Japanese with SBP of 130–139 mmHg. Trial registration　UMIN–CTR: UMIN000050671 Foundation　SoPros Inc.(Jpn Pharmacol Ther 2024;52:949‒62)